基于钆塞酸二钠增强MRI的术前评分系统预测肝内胆管癌微血管侵犯
回顾性纳入197例肝内胆管癌患者,随机分为开发集139例和验证集58例,基于钆塞酸二钠增强MRI特征建立预测微血管侵犯的评分系统,开发集AUC为0.80,验证集AUC为0.84,高微血管侵犯风险患者无复发生存期和总生存期显著更短。
要点
- 肿瘤多发、动脉期瘤周强化、肝胆期瘤周低信号是微血管侵犯的独立预测因素。
- 基于上述特征的评分系统在开发集AUC为0.80,验证集AUC为0.84。
- 高微血管侵犯风险患者无复发生存期和总生存期显著更短(p≤0.031)。
核心结论
- 基于钆塞酸二钠增强MRI特征的评分系统能有效预测肝内胆管癌患者微血管侵犯风险,有助于术前识别可能预后较差的患者。
研究设计与样本
- 回顾性纳入2009年至2016年间连续197例接受术前钆塞酸二钠增强MRI和根治性手术切除的肝内胆管癌患者,随机分为开发集139例和验证集58例,由两名放射科医生独立评估MRI特征,采用多变量逻辑回归分析建立风险评分系统并验证其诊断性能。
关键影像表现/征象
- 肿瘤多发与微血管侵犯独立相关(OR 3.37,95%CI:1.37-8.28,p=0.008)。
- 动脉期瘤周强化与微血管侵犯独立相关(OR 4.47,95%CI:1.87-10.70,p=0.001)。
- 肝胆期瘤周低信号与微血管侵犯独立相关(OR 2.96,95%CI:1.29-6.77,p=0.010)。
诊断标准与关键数值
- 评分系统预测微血管侵犯的AUC在开发集为0.80(95%CI:0.72-0.87),在验证集为0.84(95%CI:0.74-0.94)。
临床应用与阅片要点
- 该评分系统可术前评估肝内胆管癌患者微血管侵犯风险,为接受根治性手术的患者提供预后信息。
- 作者认为其使用可帮助临床医生制定个体化治疗策略以改善患者结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To develop a preoperative risk scoring system to predict microvascular invasion (MVI) in intrahepatic cholangiocarcinoma (ICCA) by incorporating clinical and gadoxetate-enhanced MRI features.
MATERIALS AND METHODS: We retrospectively enrolled 197 consecutive patients with ICCA who underwent preoperative gadoxetate-enhanced MRI and curative surgical resection between 2009 and 2016. The patients were randomly divided into a development set (n = 139) and a validation set (n = 58). Two radiologists independently reviewed the MRI features. A risk scoring system to predict MVI was developed using multivariable logistic regression analysis, and its diagnostic performance was validated. Recurrence-free survival (RFS) and overall survival (OS) were analyzed based on the MVI risk.
RESULTS: Gadoxetate-enhanced MRI features that were independently associated with MVI included tumor multiplicity (odds ratio (OR) 3.37, 95% confidence interval (CI): 1.37-8.28, p = 0.008), arterial-phase peritumoral enhancement (OR 4.47, 95% CI: 1.87-10.70, p = 0.001), and hepatobiliary-phase peritumoral hypointensity (OR 2.96, 95% CI: 1.29-6.77, p = 0.010). Using these features, the area under the receiver operating characteristic curve of the scoring system was 0.80 (95% CI: 0.72-0.87) in the development cohort and 0.84 (95% CI: 0.74-0.94) in the validation cohort. ICCA patients at high risk for MVI exhibited significantly shorter RFS and OS compared to those at low risk for MVI in both cohorts (p ≤ 0.031).
CONCLUSION: The risk scoring system based on gadoxetate-enhanced MRI features effectively predicted the risk of MVI in patients with ICCA, facilitating the preoperative identification of patients who are likely to have poorer survival outcomes following curative resection.
KEY POINTS: Question Microvascular invasion (MVI) is a well-established adverse prognostic factor in intrahepatic cholangiocarcinoma (ICCA). However, the preoperative prediction of MVI using gadoxetate-enhanced MRI remains unexplored. Findings A risk scoring system based on gadoxetate-enhanced MRI was developed, effectively predicting MVI in ICCA and linking high MVI risk to significantly poorer survival outcomes following resection. Clinical releveance This scoring system enables the accurate assessment of MVI risk in ICCA and provides valuable prognostic insights for patients undergoing curative surgery. Its use can help clinicians develop personalized treatment strategies to improve patient outcomes.
引用
- Park R, Kim DH, Choi SH, et al. Preoperative scoring system for predicting microvascular invasion in intrahepatic cholangiocarcinoma using gadoxetate-enhanced MRI. Eur Radiol. 2025. PMID: 40478346. doi:10.1007/s00330-025-11722-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。